Proteomics

Brain amyloid beta protein level analyzed, antibody effect revealed

Published in Drug Week, April 1st, 2005

A recently published study from the United States has documented the effects of a behaviorally active antibody on the brain uptake and clearance of amyloid beta protein (AbetaP).

"Antibodies directed against AbetaP have been suggested to be effective in the treatment of Alzheimer disease (AD). Here, we used in vivo and in vitro models to test some of the mechanisms by which antibodies may produce their effects," wrote W.A. Banks and colleagues, Veterans Affairs Medical Center.

"We found that the blood-to-brain uptake of murine AbetaP1-42 was significantly reduced when co-injected peripherally with an antibody known to reverse cognitive defects in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2005-04-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry